<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2204245194
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1982
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        VOLTAREN RETARD 100MG TAB
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        DICLOFENAC SODIUM
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        100
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        modified-release tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        70.45
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="NOVARTIS" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            NOVARTIS
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 439]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Novartis Saudi Limited
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            NOVARTIS
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        M01AB05
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>This medicine is used on prescription from a doctor.</p><p>Voltaren Retard is a non-steroidal anti-inflammatory drug that helps to reduce inflammation and relieve pain.</p><p>Taking Voltaren Retard can relieve symptoms of inflammation such as pain and swelling by blocking the synthesis of the molecules (prostaglandins) responsible for inflammation, pain and fever. However, it cannot treat the causes.</p><p>Voltaren Retard is particularly suitable for adult patients whose condition requires a daily dose of 75 mg or 100 mg. The ability to take a once-daily dose simplifies longer-term treatment in particular.</p><p>Voltaren Retard is used on prescription from a doctor to treat rheumatic illnesses such as osteoarthritis, soft-tissue rheumatism, painful inflammatory conditions, swelling of the back and joints, inflammation and pain following injuries and surgical procedures and gynaecological pain and inflammation.</p><p>Voltaren Retard should not be used to reduce fever only.</p><p>If you have heart disease or have significant risk factors for heart disease, your doctor will regularly re-assess whether you should continue treatment with Voltaren Retard, particularly if your treatment lasts more than 4 weeks.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Follow all the doctor&rsquo;s instructions carefully. They may differ from the general information contained in this leaflet.</p><p>&nbsp;</p><p><strong>a.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>Do not take Voltaren Tablets.&nbsp; </strong></p><p>&nbsp;</p><p>Do not use Voltaren Retard if you are allergic to any of the ingredients or have experienced difficulty breathing or allergy-like skin reactions such as swelling of the face, lips, tongue, throat and/or extremities (signs of angioedema) after taking acetylsalicylic acid or other medicines used to treat pain or inflammation (non-steroidal anti-inflammatory drugs), are in the last trimester of pregnancy, have an active ulcer of the stomach and/or small intestine (duodenal ulcer), gastrointestinal bleeding or perforation or symptoms such as bloody or black stool, chronic intestinal inflammation (Crohn&rsquo;s disease, ulcerative colitis), liver or kidney failure, severe heart failure or to treat pain following coronary bypass surgery on the heart (or use of a heart-lung machine). Voltaren Retard must not be used by children under 14 years of age.</p><p>If any of the above applies to you, tell your doctor and do not take Voltaren Retard. Your doctor will decide whether this medicine is suitable for you.</p><p>If you think you may be allergic, ask your doctor for advice.</p><p>&nbsp;</p><p><strong>b.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>Take special care with Voltaren Retard/SR tablets </strong></p><p><strong>&nbsp;</strong></p><p>Mucosal ulcers, bleeding (rare) or (in isolated cases) perforation (rupture of the stomach or intestine) may occur in the upper gastrointestinal tract during treatment with Voltaren Retard. These complications may occur at any time during treatment, even without warning symptoms. To reduce this risk, your doctor will prescribe the lowest effective dose for the shortest possible treatment period. Consult your doctor if you have stomach pain and think that it may have something to do with taking this medicine.</p><p>Caution is required if you have a heart or blood vessel disease (cardiovascular disease, including uncontrolled high blood pressure, heart failure, ischaemic heart disease or peripheral arterial disease) as treatment with Voltaren Retard is usually not recommended.</p><p>Caution is required if you have recently had surgery on your stomach/intestine or if you are soon due to have such surgery.</p><p>If you have a cardiovascular disease (see above) or significant risk factors such as high blood pressure, abnormally high levels of fat in your blood (cholesterol, triglycerides), diabetes or if you smoke, and your doctor decides to prescribe you Voltaren Retard, you must not increase the dose above 100 mg per day if you are treated for longer than 4 weeks.</p><p>It is generally important to use the lowest dose of Voltaren Retard that relieves your pain and/or swelling and to use it for the shortest time possible to keep your risk of cardiovascular side effects as low as possible.</p><p>Certain painkillers called COX-2 inhibitors have been shown to increase the risk of heart attack and stroke when given at high dosages and/or during long-term treatment. It is not known if this increased risk also applies to Voltaren Retard. If you have ever had a heart attack, stroke or venous thrombosis (blood clot in a vein) or if you have risk factors such as high blood pressure, diabetes, high levels of fat in your blood or if you smoke, your doctor will decide if you can use Voltaren Retard. If any of the above applies to you, tell your doctor.</p><p>Taking Voltaren Retard may affect the function of your kidneys, which may cause an increase in blood pressure and/or a build-up of fluid (oedema). Tell your doctor if you have heart disease or kidney disease, if you are taking medicine for high blood pressure (e.g. diuretics (&ldquo;water pills&rdquo;), ACE inhibitors), or if you experience an increase in fluid loss (e.g. through heavy sweating).</p><p>In very rare cases anti-inflammatory medicines (including Voltaren) may cause severe skin reactions (e.g. rash). Stop treatment with Voltaren Retard immediately at the first signs of any skin reaction and tell your doctor.</p><p>Furthermore, particular caution is required if you are taking Voltaren Retard at the same time as other anti-inflammatory medicines (such as acetylsalicylic acid, corticosteroids), &ldquo;blood thinners&rdquo; (anticoagulants) or selective serotonin reuptake inhibitors (SSRIs; medicines used to treat depression), if you have asthma, hay fever (seasonal allergic rhinitis), liver or kidney problems, blood clotting disorders or other problems with the blood, including a rare liver problem known as porphyria.</p><p>If any of the above applies to you, tell your doctor before you take Voltaren Retard.</p><p>If you experience any signs or symptoms of problems with your heart or blood vessels such as chest pain, shortness of breath, weakness or slurring of speech while using Voltaren Retard, contact your doctor immediately.</p><p>Voltaren Retard may reduce the signs of an infection (e.g. headache, high body temperature) and therefore make it more difficult to detect and appropriately treat the infection.</p><p>Severe skin reactions have been reported in connection with non-steroidal anti-inflammatory drug (NSAID) treatment. The risk of reactions of this type appears to be highest at the start of treatment. If you experience a skin rash, including fever, lesions of the mucous membranes, blisters or other signs of an allergy, you should stop treatment with Voltaren and seek medical treatment immediately as these may be the first signs of a very severe skin reaction (see &ldquo;Possible side effects&rdquo; section).</p><p>If you are taking Voltaren Retard for a prolonged period (more than 2 3 weeks), ensure that you do not miss your regular check-ups with your doctor.</p><p><strong>Tell your doctor or pharmacist if you: </strong></p><p>have any other illnesses</p><p>have any allergies</p><p>are taking or externally applying any other medicines (including non-prescription medicines).</p><p><strong>&nbsp;</strong></p><p>c.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Taking other medicines</p><p>Some medicines can interfere with your treatment.&nbsp; Tell your doctor or pharmacist if you are taking any of the following:</p><p>lithium or selective serotonin reuptake inhibitors (SSRIs; used to treat depression), digoxin (for heart problems), diuretics (to increase urination), ACE inhibitors or beta blockers (for high blood pressure and heart problems), other anti-inflammatory medicines such as acetylsalicylic acid or ibuprofen, corticosteroids, medicines used to prevent blood clots (anticoagulants), medicines (e.g. metformin) used to treat diabetes (except insulin), methotrexate (used to treat arthritis and cancer), ciclosporin or tacrolimus (used in organ transplantation), trimethoprim (used to treat urinary tract infections), quinolone antibiotics (a type of medicine used to treat infections), voriconazole (a medicine used to treat fungal infections), phenytoin (a medicine used to treat epileptic seizures), rifampicin (an antibiotic used to treat bacterial infections), Colestipol/cholestyramine (used to lower cholesterol), Zidovudine.</p><p>&nbsp;</p><p><strong>d.&nbsp;&nbsp; </strong><strong>Taking Voltaren Retard/</strong><strong>SR</strong><strong> tablet with food and drink</strong></p><p>Voltaren Retard/SR tablets should be swallowed whole with a glass of water or other liquid.</p><p>It is recommended to take Voltaren Retard/SR tablets during meals.</p><p><strong>&nbsp;</strong></p><p><strong>Older people</strong></p><p>Caution is required in elderly patients, particularly those who are frail or with a low body weight. They may be more sensitive to the effects of Voltaren Retard. Therefore, as a precaution, they should use the lowest effective dose.</p><p>This medicinal product contains less than 1 mmol (23 mg) of sodium per dosage unit, making it practically &ldquo;sodium-free&rdquo;.</p><p>Please only take Voltaren after talking to your doctor if you have a known intolerance to sugar.</p><p><strong>&nbsp;</strong></p><p><strong>e.&nbsp;&nbsp;&nbsp; </strong><strong>Pregnancy and breast-feeding</strong></p><p><strong>Pregnancy</strong></p><p>You should not take Voltaren unless it is absolutely necessary and you have been prescribed it by a doctor. If you are taking this medicine in the first 6 months of pregnancy, the dose should be as low as possible and treatment should last for as short a period of time as possible. Taking non-steroidal anti-inflammatory drugs (NSAIDs) from the 20th week of pregnancy onwards may harm your unborn child. If you have to take NSAIDs for more than 2 days, your doctor may have to monitor the amount of amniotic fluid in your womb.</p><p>&nbsp;</p><p>If you are pregnant or plan to become pregnant, you should only take Voltaren Retard if this has been discussed with your doctor. Do not take Voltaren Retard in the last trimester of pregnancy.</p><p><strong>Breast-feeding</strong></p><p>Voltaren Retard should not be taken during breast-feeding unless your doctor has expressly allowed you to do so.</p><p><strong>&nbsp;</strong></p><p><strong>e. Driving and using machines</strong></p><p>This medicine may affect your reactions and your ability to drive or use tools or machines.</p><p>If you experience dizziness, visual disturbances or other central nervous system disorders in particular, do not drive or use machines and consult your doctor immediately.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Dosage and administration will be decided by your doctor based on the condition being treated and the severity of your symptoms. Follow your doctor&rsquo;s instructions carefully. Do not exceed the recommended daily dose and treatment duration prescribed by your doctor.</p><p>If you use Voltaren Retard for longer than a few weeks, you should consult your doctor for regular check-ups to ensure that you are not experiencing any unnoticed side effects.</p><p>At the start of treatment the daily dose is generally 100 150 mg. In milder cases and for long-term treatment 75 100 mg daily (one 75 mg or 100 mg Voltaren Retard coated tablet in the morning or evening) is generally sufficient.</p><p>To prevent pain in the night or stiffness in the morning, take Voltaren Retard in the evening.</p><p>If necessary, the daily dose may be increased to 150 mg (two 75 mg coated tablets or one 100 mg coated tablet in combination with 25 mg or 50 mg coated tablets or suppositories), preferably taken as separate doses spread over the course of the day. Voltaren Retard coated tablets should be taken whole. They are best taken with a large amount of liquid and preferably taken with meals. Do not chew or divide the coated tablets.</p><p>Do not change the prescribed dosage yourself. If you think the effect of your medicine is too weak or too strong, talk to your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The following side effects may occur when taking/using Voltaren:</p><p><strong>Common (affects 1 to 10 in 100 users)</strong></p><p>Headache, light-headedness, dizziness, nausea, vomiting, diarrhoea, stomach problems, abdominal pain, flatulence, decreased appetite, rash, fluid build-up, swelling, increased blood pressure, change in liver function (e.g. increased liver enzyme concentration in the blood).</p><p><strong>Uncommon (affects 1 to 10 in 1,000 users)</strong></p><p>(Occur particularly when taking a high daily dose (150 mg) over a longer period): sudden chest pain with a sensation of tightness/heaviness (sign of a heart attack); difficulty breathing, difficulty breathing when lying down, swelling of the feet or legs (signs of heart failure).</p><p><strong>Rare (affects 1 to 10 in 10,000 users)</strong></p><p>Hypersensitivity reactions (allergic reactions) with swelling in the face, mouth, limbs (may include decreased blood pressure and shock), asthma, drowsiness, inflammation and ulcers of the gastrointestinal tract, vomiting blood, bloody diarrhoea, jaundice (very rare: liver failure), liver inflammation, liver function problems, hives. Unknown frequency: sudden chest pain and allergic reactions (signs of Kounis syndrome).</p><p><strong>Very rare (affects fewer than 1 in 10,000 users) </strong></p><p>Changes in blood count, unusual bleeding, bruising, mental health problems (including sleeplessness, irritability), discomfort, memory problems, convulsions, anxiety, tremor, abnormal sense of taste, visual disturbance*, visual impairment, noises in the ear(s), reduced hearing, stiff neck, inflammation of the blood vessels/lungs/large intestine, constipation, pancreas inflammation, inflammation of the mucous membranes of the mouth, tongue inflammation, eczema, itching, inflamed, red skin, hair loss, bleeding skin, acute kidney problems, blood in the urine.</p><p><strong>*Visual disturbance:</strong> If you experience symptoms of a visual disturbance during treatment with Voltaren Retard, contact your doctor. An eye examination may be considered to rule out other causes.</p><p>&nbsp;</p><p><strong>Frequency not known:</strong> A severe skin reaction known as DRESS syndrome may occur. Symptoms of DRESS include skin rash, fever, swollen lymph nodes and an increase in eosinophils (a type of white blood cell).</p><p>&nbsp;</p><p>Tell your doctor if you experience any of these side effects.</p><p>If you notice any side effects which are not described here, tell your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Do not use after the expiry date (= EXP) printed on the pack.</p><p><strong>Storage instructions </strong></p><p>Keep out of the reach of children.</p><p>Protect the 75 mg and 100 mg coated tablets from moisture.</p><p>Do not store above 30&deg;C.</p><p><strong>Additional information</strong></p><p>Your doctor or pharmacist will be able to give you more information. They have access to the full prescribing information.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>1 coated tablet contains 75 mg or 100 mg diclofenac sodium and other ingredients.</p><p><strong>Active substances</strong></p><p>Diclofenac sodium</p><p><strong>Other ingredients</strong></p><p><strong>75 mg coated tablets:</strong> Sucrose, cetyl alcohol, povidone K30, silica, magnesium stearate, hypromellose, talc, polysorbate 80, polyethylene glycol 8000 (macrogol 8000a), titanium dioxide (E171), iron oxide red (E172), shellac, iron oxide black (E172), propylene glycol.</p><p><strong>100 mg coated tablets:</strong> Sucrose, cetyl alcohol, povidone K30, silica, magnesium stearate, hypromellose, talc, polysorbate 80, polyethylene glycol 8000 (macrogol 8000a), titanium dioxide (E171), iron oxide red (E172), propylene glycol.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Available only in pharmacies with a doctor’s prescription.
75 mg coated tablets: Packs of 20 tablets.
100 mg coated tablets: Packs of 10, 30 tablets.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The Marketing Authorization Holder for this Product is Novartis Pharma AG.</p><p>www.Novartis.com &nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last approved by Swiss Medic in 09 / 2022

e. To report any side effect(s):
Saudi Arabia

The National Pharmacovigilance Centre (NPC):

o Fax: +966-11-205-7662
o SFDA call center: 19999
o E-mail: npc.drug@sfda.gov.sa
o Website: https://ade.sfda.gov.sa 

Patient Safety Department Novartis Consulting AG - Saudi Arabia:
o Toll Free Number: 8001240078
o Phone: +966112658100 
o Fax: +966112658107
o Email: adverse.events@novartis.com  

•    Other GCC States:
-  Please contact the relevant competent authority.


This is a Medicament
-   Medicament  is  a  product  which  affects  your  health  and  its  consumption  contrary  to 
instructions is dangerous for you.
-   Follow strictly the doctor’s prescription, the method of use and the instructions of the 
pharmacist who sold the medicament.
-   The doctor and the pharmacist are the experts in medicines, their benefits and risks.
-  Do not by yourself interrupt the period of treatment prescribed for you.
-   Do not repeat the same prescription without consulting your doctor.
-   Keep all medicaments out of reach of children.
                                                              

Council of Arab Health Ministers
Union of Arab Pharmacists

f. This patient information leaflet is approved by the Saudi Food and Drug Authority

            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يستخدم هذا الدواء بوصفة طبية من طبيب.</p><p dir="RTL">عقار فولتارين ممتد المفعول هو واحدًا من مجموعة أدوية تُسَمَّى مضادات الالتهاب غير الستيرويدية، يساعد على الحد من الألم والالتهاب. يعمل فولتارين على تخفيف أعراض الالتهاب، مثل الألم والتورم، من خلال صد تخليق الجزيئات (البروستاجلاندين) المسؤولة عن الالتهاب، والألم، والحمى. وهو لا يزاول أي تأثير على أسباب الالتهاب أو الحمى.</p><p dir="RTL">&nbsp;</p><p dir="RTL">فولتارين ممتد المفعول مناسب بشكل خاص للمرضى البالغين الذين تتطلب حالتهم جرعة يومية من 75 مجم أو 100 مجم. القدرة على تناول جرعة واحدة يوميًا يبسط العلاج طويل الأمد على وجه الخصوص.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يستخدم فولتارين ممتد المفعول بوصفة طبية من الطبيب لعلاج الأمراض الروماتيزمية مثل هشاشة العظام ، وروماتيزم الأنسجة الرخوة ، والحالات الالتهابية المؤلمة ، وتورم الظهر والمفاصل ، والالتهاب والألم بعد الإصابات والعمليات الجراحية وآلام والتهابات أمراض النساء.</p><p dir="RTL">&nbsp;&nbsp;</p><p dir="RTL">لا ينبغي استخدام فولتارين ممتد المفعول لتقليل الحمى فقط.</p><p dir="RTL">إذا كنت تعاني من أمراض القلب أو لديك مخاطر هامة متعلقة بمرض القلب ، فسيقوم طبيبك بإعادة تقييم ما إذا كان يجب عليك مواصلة العلاج باستخدام فولتارين ممتد المفعول، لا سيما إذا كنت تتلقى العلاج لأكثر من 4 أسابيع.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">التزم بجميع تعليمات طبيبك بكل دقة. هذه التعليمات قد تكون مختلفة عن المعلومات العامة المذكورة في هذه النشرة.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>أ&zwnj;.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>موانع استعمال عقار فولتارين ممتد</strong><strong> المفعول</strong></p><p dir="RTL">لا تستخدم فولتارين ممتد المفعول إذا كنت تعاني من حساسية تجاه أي من المكونات أو كنت تعاني من صعوبة في التنفس أو تفاعلات جلدية تشبه الحساسية مثل تورم الوجه والشفتين واللسان والحلق و / أو الأطراف (علامات الوذمة الوعائية) بعد تناول حمض أسيتيل الساليسيليك أو الأدوية الأخرى المستخدمة لعلاج الألم أو الالتهاب (العقاقير غير الستيرويدية المضادة للالتهابات)، لديك قرحة نشطة في المعدة و / أو الأمعاء الدقيقة (قرحة الاثني عشر) ، ونزيف الجهاز الهضمي أو انثقاب أو أعراض مثل البراز الدموي أو الأسود ، والتهاب الأمعاء المزمن (مرض كرون ، والتهاب القولون التقرحي) ، وفشل الكبد أو الكلى ، وفشل القلب الحاد أو لعلاج الألم بعد جراحة المجازة التاجية على القلب (أو استخدام جهاز القلب والرئة)، إذا كنتِ حاملاً في الشهور الثلاثة الأخيرة من الحمل.</p><p dir="RTL">يجب عدم استخدام فولتارين ممتد المفعول من قبل الأطفال الذين تقل أعمارهم عن 14 عامًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كان أي مما سبق ينطبق عليك ، أخبر طبيبك ولا تتناول فولتارين ممتد المفعول. سيقرر طبيبك ما إذا كان هذا الدواء مناسبًا لك.</p><p dir="RTL">إذا كنت تعتقد أنك قد تكون مصابًا بالحساسية ، فاطلب النصيحة من طبيبك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>ب&zwnj;.&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>الاحتياطات عند استعمال </strong><strong>عقار فولتارين </strong><strong>ممتد المفعول</strong></p><p dir="RTL">قد تحدث تقرحات مخاطية ، نزيف (نادر) أو (في حالات منعزلة) ثقب (تمزق في المعدة أو الأمعاء) في الجهاز الهضمي العلوي أثناء العلاج باستخدام فولتارين ممتد المفعول. قد تحدث هذه المضاعفات في أي وقت أثناء العلاج ، حتى بدون أعراض تحذيرية. لتقليل هذا الخطر ، سيصف طبيبك أقل جرعة فعالة لأقصر فترة علاج ممكنة. استشر طبيبك إذا كنت تعاني من آلام في المعدة وتعتقد أنه قد يكون لها علاقة بتناول هذا الدواء.</p><p dir="RTL">&nbsp;يجب توخي الحذر إذا كنت تعاني من أمراض القلب أو الأوعية الدموية (أمراض القلب والأوعية الدموية ، بما في ذلك ارتفاع ضغط الدم غير المنضبط أو قصور القلب الاحتقاني أو الإصابة بمرض نقص تروية القلب أو أمراض الشرايين الطرفية) حيث لا ينصح عمومًا العلاج بعقار فولتارين.</p><p dir="RTL">يجب توخي الحذر إذا أجريت مؤخرًا عملية جراحية في معدتك / أمعائك أو إذا كنت قريبًا على وشك إجراء مثل هذه الجراحة.</p><p dir="RTL">إذا كنت تعاني من أمراض القلب والأوعية الدموية (انظر أعلاه) أو عوامل خطر كبيرة مثل ارتفاع ضغط الدم ، ومستويات عالية بشكل غير طبيعي من الدهون في الدم (الكوليسترول والدهون الثلاثية) ، ومرض السكري أو إذا كنت تدخن ، وقرر طبيبك أن يصرف فولتارين ، يجب ألا تزيد الجرعة عن 100 مجم في اليوم إذا تم علاجك لمدة تزيد عن 4 أسابيع.</p><p dir="RTL">&nbsp;</p><p dir="RTL">من المهم بصفة عامة أن تأخذ أدنى جرعة من فولتارين قادرة على تخفيف الألم و/أو التورم ولأقصر مدة ممكنة لتقليل مخاطر إصابتك بآثار جانبية إلى أدنى حد ممكن.</p><p dir="RTL">ثبت أن بعض المسكنات التي تسمى مثبطات COX-2 تزيد من خطر الإصابة بالنوبات القلبية والسكتة الدماغية عند إعطائها بجرعات عالية و / أو أثناء العلاج طويل الأمد. من غير المعروف ما إذا كان هذا الخطر المتزايد ينطبق أيضًا على عقار فولتارين ممتد المفعول، إذا أصبت في أي وقت بنوبة قلبية أو سكتة دماغية أو تجلط وريدي (جلطة دموية في الوريد) أو إذا كان لديك عوامل خطر مثل ارتفاع ضغط الدم أو السكري أو ارتفاع مستويات الدهون في الدم أو إذا كنت تدخن ، فسيقرر طبيبك إذا كنت تستطيع استخدام عقار فولتارين. إذا انطبق عليك أي مما سبق ، أخبر طبيبك.</p><p dir="RTL">قد يؤثر تناول عقار فولتارين على وظيفة كليتيك ، مما قد يتسبب في زيادة ضغط الدم و / أو تراكم السوائل (الوذمة). أخبر طبيبك إذا كنت تعاني من أمراض القلب أو أمراض الكلى ، إذا كنت تتناول أدوية لارتفاع ضغط الدم (مثل مدرات البول (&quot;حبوب الماء&quot;) ، مثبطات الإنزيم المحول للأنجيوتنسين) ، أو إذا كنت تعاني من زيادة في فقدان السوائل (على سبيل المثال من خلال التعرق الشديد) .</p><p dir="RTL">&nbsp;</p><p dir="RTL">في حالات نادرة جدًا ، قد تسبب الأدوية المضادة للالتهابات (بما في ذلك عقار فولتارين) &nbsp;تفاعلات جلدية شديدة (مثل الطفح الجلدي). توقف عن العلاج باستخدام عقار فولتارين ممتد المفعول فور ظهور العلامات الأولى لأي تفاعل جلدي وأخبر طبيبك.</p><p dir="RTL">علاوة على ذلك ، يجب توخي الحذر بشكل خاص إذا كنت تتناول عقار فولتارين ممتد المفعول في نفس الوقت مع الأدوية الأخرى المضادة للالتهابات (مثل حمض أسيتيل الساليسيليك ، الكورتيكوستيرويدات) ، &quot; الأدوية التي تسبب سيولة الدم&quot; (مضادات التخثر) أو مثبطات امتصاص السيروتونين الانتقائية (SSRIs ؛ الأدوية المستخدمة في علاج الاكتئاب) ، إذا كنت تعاني من الربو ، حمى القش (التهاب الأنف التحسسي الموسمي) ، مشاكل الكبد أو الكلى ، اضطرابات تخثر الدم أو مشاكل أخرى في الدم ، بما في ذلك مشكلة الكبد النادرة المعروفة باسم البورفيريا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كان أي مما سبق ينطبق عليك ، أخبر طبيبك قبل أن تأخذ عقار فولتارين ممتد المفعول.</p><p dir="RTL">إذا كنت تعاني من أي علامات أو أعراض لمشاكل في القلب أو الأوعية الدموية مثل ألم في الصدر أو ضيق في التنفس أو ضعف أو تشوش في الكلام أثناء استخدام عقار فولتارين ممتد المفعول ، فاتصل بطبيبك على الفور.</p><p dir="RTL">قد يؤدي فولتارين إلى تقليل أعراض العدوى (مثل الصداع، ارتفاع حرارة الجسم) وبالتالي فإنه قد يُزيد من صعوبة اكتشاف العدوى وعلاجها بالشكل المناسب.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تم الإبلاغ عن تفاعلات جلدية شديدة مرتبطة بعلاج العقاقير غير الستيرويدية المضادة للالتهابات (NSAID). يبدو أن خطر حدوث تفاعلات من هذا النوع يكون أعلى في بداية العلاج. إذا كنت تعاني من طفح جلدي ، بما في ذلك الحمى ، وآفات الأغشية المخاطية ، أو البثور أو غيرها من علامات الحساسية ، يجب عليك التوقف عن العلاج باستخدام عقار فولتارين وطلب العلاج الطبي على الفور لأن هذه قد تكون العلامات الأولى لرد فعل جلدي شديد (انظر قسم &quot;الأعراض الجانبية المحتملة&quot;).</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كنت تتناول عقار فولتارين ممتد المفعول لفترة طويلة (أكثر من 2 &ndash; 3 &nbsp;أسابيع) ، فتأكد من عدم تفويت فحوصاتك المنتظمة مع طبيبك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أخبر طبيبك أو الصيدلي:</strong></p><p dir="RTL">إذا كان لديك أي أمراض أخرى</p><p dir="RTL">إذا كان لديك أي حساسية</p><p dir="RTL">إذا كنت تأخذ أو تستخدم خارجيًا أي أدوية أخرى (بما في ذلك الأدوية بدون وصفة طبية).</p><p dir="RTL">&nbsp;</p><p dir="RTL">ج. التداخلات الدوائية من أخذ عقار فولتارين طويل المفعول مع أدوية أخرى أو أعشاب أو مكملات غذائية</p><p dir="RTL">يمكن لبعض الأدوية أن تتداخل مع علاجك. أخبر طبيبك أو الصيدلي إذا كنت تتناول أيًا مما يلي:</p><p dir="RTL">الليثيوم أو مثبطات امتصاص السيروتونين الانتقائية (SSRIs ) (أدوية تُستعمَل لعلاج بعض أنواع الاكتئاب) ، الديجوكسين (دواء يُستعمَل في أمراض القلب) ، مدرات البول (أدوية تُستعمل لزيادة كمية البول) ، مثبطات الإنزيم المحول للأنجيوتنسين أو حاصرات بيتا (لارتفاع ضغط الدم ومشاكل القلب) ، الأدوية الأخرى المضادة للالتهابات مثل حمض أسيتيل الساليسيليك أو الإيبوبروفين ، الكورتيكوستيرويدات ، الأدوية المستخدمة لمنع تجلط الدم (مضادات التخثر) ، الأدوية (مثل الميتفورمين) المستخدمة لعلاج مرض السكري (باستثناء الأنسولين) ، الميثوتريكسات (يستخدم لعلاج التهاب المفاصل والسرطان) ، سيكلوسبورين أو تاكروليموس (أدوية تُستعمَل للمرضى الذين تلقوا زرع أعضاء) ، ترايميثوبريم (دواء يُستعمَل للوقاية أو لعلاج عدوى المسالك البولية)، مضادات البكتريا من نوع الكينولون (أدوية تُستعمَل ضد العدوى)، فوريكونازول (دواء يستخدم لعلاج العدوى الفطرية)، الفينيتوين (دواء يستخدم لعلاج التشنجات) ، ريفامبيسين (مضاد حيوي يستعمل لعلاج العدوى البكتيرية) ، كوليستيبول / كوليسترامين (يستخدم لخفض الكوليسترول) ، زيدوفودين.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>دـ. تناول فولتارين مع الطعام والشراب</strong></p><p dir="RTL">يجب ابتلاع أقراص فولتارين ممتد المفعول كاملة مع كوب من الماء أو غيره من السوائل.</p><p dir="RTL">يوصى بتناول أقراص فولتارين ممتد المفعول أثناء الوجبات.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ا<strong>لمسنون</strong></p><p dir="RTL">قد يكون المرضى المسنون، خاصة ممن يعانون من انخفاض الوزن، أكثر حساسية لآثار فولتارين عن البالغين الآخرين. يجب عليهم الالتزام بتعليمات الطبيب بكل دقة وأن يأخذوا أقل جرعة تصلح للحالة التي يعانون منها. من المهم على نحو خاص أن يقوم المرضى المسنون بإبلاغ طبيبهم فوراً عن أي آثار غير مرغوبة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يحتوي هذا المنتج الطبي على أقل من 1 مليمول (23 مجم) من الصوديوم لكل وحدة جرعة ، مما يجعله عمليًا &quot;خاليًا من الصوديوم&quot;.</p><p dir="RTL">يرجى تناول عقار فولتارين فقط بعد التحدث مع طبيبك إذا كان لديك عدم تحمل معروف للسكر.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>هـ. الحمل والرضاعة </strong></p><p dir="RTL"><strong>الحمل</strong></p><p dir="RTL">يجب ألا تتناولي عقار فولتارين إلا إذا كان ذلك ضروريًا للغاية وقد وصفه لك الطبيب. إذا كنت تتناولي هذا الدواء في الأشهر الستة الأولى من الحمل ، فيجب أن تكون الجرعة منخفضة قدر الإمكان ويجب أن يستمر العلاج لأقصر فترة زمنية ممكنة. قد يؤدي تناول العقاقير غير الستيرويدية المضادة للالتهابات (NSAIDs) من الأسبوع العشرين من الحمل فصاعدًا إلى الإضرار بجنينك. إذا كان عليك تناول مضادات الالتهاب غير الستيروئيدية لأكثر من يومين ، فقد يتعين على طبيبك مراقبة كمية السائل الأمنيوسي في رحمك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كنت حاملاً أو تخططين للحمل ، يجب ألا تأخذي عقار فولتارين إلا إذا تمت مناقشة ذلك مع طبيبك. لا تأخذي عقار فولتارين في الأشهر الثلاثة الأخيرة من الحمل.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الرضاعة الطبيعية</strong></p><p dir="RTL">لا ينبغي أن يؤخذ عقار فولتارين أثناء الرضاعة الطبيعية إلا إذا سمح لك طبيبك بذلك.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>و.</strong><strong> </strong><strong>تأثير عقار </strong><strong>فولتارين </strong><strong>طويل المفعول </strong><strong>على القيادة واستخدام الآلات</strong></p><p dir="RTL">قد يؤثر هذا الدواء على ردود أفعالك وقدرتك على القيادة أو استخدام الأدوات أو الآلات.</p><p dir="RTL">إذا شعرت بدوخة أو اضطرابات بصرية أو اضطرابات أخرى بالجهاز العصبي المركزي على وجه الخصوص ، فلا تقود السيارة أو تستخدم الآلات واستشر طبيبك على الفور.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">سيحدد طبيبك الجرعة بناءً على الحالة التي يتم علاجها وشدة الأعراض. اتبع تعليمات طبيبك بعناية. لا تتجاوز الجرعة اليومية الموصى بها ومدة العلاج التي حددها طبيبك.</p><p dir="RTL">إذا كنت تستخدم عقار فولتارين ممتد المفعول لمدة تزيد عن بضعة أسابيع ، يجب عليك استشارة طبيبك لإجراء فحوصات منتظمة للتأكد من أنك لا تعاني من أي آثار جانبية غير ملحوظة.</p><p dir="RTL">في بداية العلاج تكون الجرعة اليومية بصفة عامة 100 إلى 150 مجم. تؤخذ حبة واحدة لفولتارين ممتدة المفعول 100 مجم أو على شكل حبتين في اليوم لأقراص فولتارين ممتدة المفعول 75 مجم. &nbsp;في الحالات الأخف، وفي العلاج طويل الأجل، يكفي عادة استعمال 75 إلى 100 مجم يومياً. &nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">لمنع الألم في الليل أو التيبس في الصباح ، تناول عقار فولتارين في المساء.</p><p dir="RTL">إذا لزم الأمر ، يمكن زيادة الجرعة اليومية إلى 150 مجم (قرصان مغلفان عيار 75 مجم أو قرص واحد مغلف 100 مجم بالاشتراك مع 25 مجم أو 50 مجم من الأقراص أو التحاميل) ، ويفضل تناولها كجرعات منفصلة موزعة على مدار اليوم يجب أن تؤخذ أقراص عقار فولتارين المغلفة كاملة. من الأفضل تناولها بكمية كبيرة من السائل ويفضل تناولها مع الوجبات. لا تمضغ أو تقسم الأقراص المغلفة.</p><p dir="RTL">لا تغير الجرعة الموصوفة بنفسك. إذا كنت تعتقد أن تأثير الدواء الخاص بك ضعيف جدًا أو قوي جدًا ، تحدث إلى طبيبك أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">قد يُسبب تناول/استخدام عقار فولتارين الآثار الجانبية التالية:</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong><u>شائعة (تصيب 1 إلى 10 من كل 100 مستخدم)</u></strong></p><p dir="RTL">صداع ، خفة الرأس ، دوار ، غثيان ، قيء ، إسهال ، مشاكل في المعدة ، ألم بطني ، انتفاخ البطن ، انخفاض الشهية ، طفح جلدي ، تراكم السوائل ، انتفاخ ، زيادة ضغط الدم ، تغير في وظائف الكبد (مثل زيادة تركيز إنزيم الكبد في الدم).</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong><u>غير شائعة (تصيب 1 إلى 10 من كل 1000 مستخدم)</u></strong></p><p dir="RTL">(تحدث بشكل خاص عند تناول جرعة يومية عالية (150 مجم) على مدى فترة أطول): ألم مفاجئ في الصدر مع إحساس بالضيق / الثقل (علامة على نوبة قلبية) ؛ صعوبة في التنفس ، صعوبة في التنفس عند الاستلقاء ، تورم القدمين أو الساقين (علامات قصور في القلب).</p><p dir="RTL">&nbsp;</p><p><strong><u>نادرة (تصيب 1 إلى 10 من كل 10000 مستخدم)</u></strong></p><p dir="RTL">تفاعلات فرط الحساسية (تفاعلات حساسية) مع انتفاخ في الوجه والفم والأطراف (قد تشمل انخفاض ضغط الدم والصدمة) ، والربو ، والنعاس ، والتهاب وتقرحات الجهاز الهضمي ، وتقيؤ الدم ، والإسهال الدموي ، واليرقان (نادر جدًا: فشل الكبد ) ، التهاب الكبد ، مشاكل في وظائف الكبد ، طفح جلدي. مصادفة حدوث ألم في الصدر و تفاعلات تحسسية (علامات متلازمة كونيس).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong><u>نادرة جدًا (تصيب أقل من 1 من بين 10000 مستخدم)</u></strong></p><p dir="RTL">تغيرات في تعداد الدم ، نزيف غير عادي ، كدمات ، صعوبة في النوم (من علامات الأرق)، كوابيس، تهيج ، وعدم الراحة ، ومشاكل الذاكرة ، والتشنجات ، والقلق ، والرعاش ، خلل في المذاق (من علامات خلل حاسة التذوق)، اضطرابات بصرية* ، وضعف البصر ، والضوضاء في الأذن (من علامات الطنين) ، ضعف السمع ، تيبس الرقبة ، التهاب الأوعية الدموية / الرئتين / الأمعاء الغليظة ، الإمساك ، التهاب البنكرياس ، التهاب الأغشية المخاطية للفم ، التهاب اللسان ، الأكزيما ، الحكة ، التهاب الجلد الأحمر ، تساقط الشعر ، نزيف الجلد ، مشاكل الكلى الحادة ، دم في البول.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>* إضطرابات الرؤية:</strong> إذا ظهرت أعراض اضطراب الرؤية خلال فترة العلاج بعقار فولتارين، راجع طبيبك فقد تحتاج إلى فحص العين، كي يتم استبعاد أي أسباب أخرى.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد يحدث تفاعل جلدي شديد يعرف بمتلازمة DRESS تشمل أعراض DRESS الطفح الجلدي والحمى وتضخم الغدد الليمفاوية وزيادة الحمضات (نوع من خلايا الدم البيضاء).</p><p dir="RTL">&nbsp;</p><p dir="RTL">أخبر طبيبك إذا واجهت أيًا من هذه الآثار الجانبية.</p><p dir="RTL">إذا لاحظت أي آثار جانبية غير موصوفة هنا ، أخبر طبيبك أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">لا تستخدم عقار فولتارين طويل المفعول بعد انتهاء تاريخ الصلاحية المطبوع على الجزء الخارجي من العبوة.</p><p dir="RTL"><strong>إرشادات التخزين</strong></p><p dir="RTL">تبقى بعيدًا عن متناول الأطفال.</p><p dir="RTL">يحفظ عقار فولتارين طويل المفعول في مكان جاف، في درجة حرارة أقل من 30 درجة مئوية.</p><p dir="RTL"><strong>معلومات إضافية</strong></p><p dir="RTL">اسأل طبيبك أو الصيدلي عند الحاجة لمزيد من المعلومات.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <ul><li dir="RTL"><strong>أقراص فولتارين ممتدة المفعول 75 مجم </strong></li></ul><p dir="RTL">عقار فولتارين طويل المفعول تحتوي على 75 مجم من المادة الفعالة، ديكلوفيناك الصوديوم.&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>المواد الأخرى:</strong> تحتوي أقراص فولتارين 75 مجم ممتدة المفعول على; كحول سيتيلي، ستيرات الماغنيسيوم ،بوفيدون، سيليكا ، كولويد انهايدروس (غروي لا مائي) سكروز، أكسيد الحديد الأحمر(E172)،&nbsp; ماكروجول 8000، بوليسوربات 80 ، تلك، ثاني أكسيد التيتانيوم (E171).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>أقراص فولتارين ممتدة المفعول 100 مجم</strong></p><p dir="RTL"><strong>&nbsp;</strong>عقار فولتارين طويل المفعول وتحتوي على 100 مجم من المادة الفعالة، ديكلوفيناك الصوديوم.&nbsp;</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>المواد الأخرى:</strong> تحتوي أقراص فولتارين 100 مجم ممتدة المفعول على; كحول سيتيلي، ستيرات الماغنيسيوم ،بوفيدون، سيليكا ، كولويد انهايدروس (غروي لا مائي) سكروز، أكسيد الحديد الأحمر(E172)، هيبروميلوز، ماكروجول 8000، بوليسوربات 80 ، تلك، ثاني أكسيد التيتانيوم (E171) ،وحبر الطباعة على القرص: أكسيد الحديد الأسود، شيلاك (صَمْغُ اللَّك)</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <ul><li dir="RTL"><strong>أقراص فولتارين ممتدة المفعول 75 مجم </strong></li></ul><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يتوفر عقار فولتارين طويل المفعول في عبوات شرائط تحتوي على 20 قرصًا.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عبارة عن أقراص مثلثة &nbsp;ذات لون وردي شاحب عليها علامة CG على أحد جانبيها وID على الجانب الآخر،</p><p dir="RTL">&nbsp;</p><ul><li dir="RTL"><strong>أقراص فولتارين ممتدة المفعول 100 مجم </strong></li></ul><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يتوفر عقار فولتارين طويل المفعول في عبوات شرائط تحتوي على 10 أو 30 قرصًا.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عبارة عن أقراص مثلثة &nbsp;ذات لون أحمر عليها علامة CG على أحد جانبيها وCGC على الجانب الآخر،</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد لا تكون جميع العبوات مسوقة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مالك حق التسويق لهذا المنتج هي شركة نوفارتس فارما إيه جي.</p><p dir="RTL">www.Novartis.com</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تم اعتماد هذه النَّشرة من قبل الوكالة السويسرية للمنتجات العلاجية في تاريخ  09/2022


جـ.  للإبلاغ عن الأعراض الجانبية : 
•	المملكة العربية السعودية

   - المركز الوطني للتيقظ والسلامة الدوائية (NPC)
الفاكس: +966-11-205-7662
مركز اتصال الهيئة السعودية للغذاء والدواء: 19999
البريد الالكتروني: npc.drug@sfda.gov.sa
الموقع الالكتروني: https://ade.sfda.gov.sa

-	شركة نوفارتس - السعودية - قسم سلامة المرضى:
الهاتف المجاني: 8001240078
الهاتف:  +966112658100
الفاكس: +966112658107
البريد الالكتروني: adverse.events@novartis.com

دول مجلس التَّعاون الخليجي الأخرى: 
- يُرجى الاتصال بسلطات الاختصاص المعنية



إن هذا الدواء
-	الدَّواء مستحضر يُؤثر على صحتك واستهلاكه خلافًا للتَّعليمات يعرضك للخطر. 
-	اتبع بدقة وصفة الطبيب وطريقة الاستعمال المنصوص عليها وتعليمات الصيدلي الذي صرفها لك
-	إن الطبيب والصيدلي هما الخبيران في الدواء وبنفعه و ضرره.
-	لا تقطع مدة العلاج المحددة لك من تلقاء نفسك 
-	لا تكرر صرف الدواء بدون استشارة الطبيب.
-	لا تترك الأدوية في مُتناوَل أيدي الأطفال.


                                                                 مجلس وزراء الصحة العرب
                                                                 اتحاد الصيادلة العرب

ح.	تم اعتماد نشرة معلومات المريض هذه من قبل الهيئة السعودية العامة للغذاء والدَّواء.

        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Voltaren 75mg SR tablets
Voltaren 100mg Retard tablets	

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                The active substance is: Diclofenac sodium (phenylacetic acid derivative).
Each sustained release tablet contains 75 mg or 100 mg diclofenac sodium Ph.Eur.

Sodium content per dosage unit	Sodium content per unit
75 mg prolonged-release tablet	5.415 mg/prolonged-release tablet
100 mg prolonged-release tablet	7.22 mg/prolonged-release tablet

For a full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Prolonged-release, coated tablets.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inflammatory and degenerative forms of rhumatism: rhumatoid arthritis, ankylosing spondylitis, osteaarthritis including spondyloarthritis,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Painful syndromes of the vertebral column.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Non-articular rheumatism.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Painful Post-traumatic and post-operative inflammation and swelling, e.g. following dental or orthopedic surgery.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Painful and/or inflammatory gynaecological conditions, e.g. primary dysmenorrhoea or adnexitis.</p><p>&nbsp;</p><p>In keeping with standard therapeutic principles, the underlying disease should be treated with specific therapy as appropriate. Fever alone is not an indication.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>As a general recommendation, the dose should be individually adjusted. Adverse effects may be minimised by using the lowest effective dose for the shortest duration necessary to control symptoms (see section 4.4 Special warnings and precautions for use).</p><p>&nbsp;</p><p>For oral administration</p><p>&nbsp;</p><p><strong>General Target population - Adults:</strong></p><p>&nbsp;</p><p>The usual daily dose of Voltaren Retard is 100-150 mg, i.e. one 100 mg prolonged-release coated tablet, or two 75 mg prolonged-release coated tablets. In milder cases and for long-term therapy, one 75 mg or 100 mg prolonged-release coated tablet per day is normally sufficient. If symptoms are most pronounced at night or in the morning, Voltaren Retard should preferably be taken in the evening.</p><p>&nbsp;</p><p>The prolonged-release coated tablets should be swallowed whole with liquid, preferably with meals.</p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong>Special populations</strong></p><p>&nbsp;</p><p><strong>Paediatric population</strong><em> </em><em>(below 18 years of age)</em></p><p>Voltaren 75&nbsp;mg and 100&nbsp;mg prolonged release tablets are not suitable for children and adolescents.</p><p><strong>&nbsp;</strong></p><p><strong>Elderly </strong><em>(aged 65 or above)</em></p><p>No adjustment of the starting dose is generally required for elderly patients. However, caution is indicated on basic medical grounds, especially for frail elderly patients or those with a low body weight (see Section 4.4 &ldquo;Special warnings and precautions for use&quot;).</p><p>&nbsp;</p><p><strong>Established cardiovascular disease or significant cardiovascular risk factors</strong></p><p>Treatment with Voltaren is generally not recommended in patients with established cardiovascular disease or uncontrolled hypertension. If needed, patients with established cardiovascular disease, uncontrolled hypertension or significant risk factors for cardiovascular disease should be treated with Voltaren only after careful consideration, and only at doses of up to 100 mg daily if treated for more than 4 weeks (see sSection 4.4 &ldquo;Special warnings and precautions for use&quot;).</p><p><strong>&nbsp;</strong></p><p><strong>Renal impairment</strong></p><p>Voltaren is contraindicated in patients with renal impairment (GFR &lt;15&nbsp;ml/min/1.73&nbsp;m<sup>2</sup> ) (see section 4.3 contraindication).&nbsp;</p><p>No specific studies have been carried out in patients with renal impairment, thereforeno specific dose adjustment recommendations can be made. Caution is advised when administering diclofenac to patients with renal impairment (see section 4.4 Special Warnings and precautions for use&quot;).</p><p>&nbsp;</p><p><strong>Hepatic impairment</strong></p><p>Voltaren is contraindicated in patients with hepatic impairment (see section 4.3 contraindication).&nbsp;</p><p>No specific studies have been carried out in patients with hepatic impairment, therefor, no specific dose adjustment recommendations can be made. Caution is advised when administering Voltaren to patients with mild to moderate hepatic impairment (see section 4.4 Special Warnings and precautions for use).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                •	Hypersensitivity to the active substance or any of the excipients. indicated under section 6.1 
•	A history of bronchospasm, angioedema, urticaria, acute rhinitis, nasal polyps or allergy-like symptoms after taking acetylsalicylic acid or other non-steroidal anti-inflammatory drugs.
•	Third trimester of pregnancy (see section 4.6 Pregnancy and lactation).
•	Active gastric and/or duodenal  ulcer, gastrointestinal bleeding or perforation. 
•	Inflammatory bowel disease (such as Crohn’s disease or ulcerative colitis).
•	Hepatic failure (Child-Pugh class C) (cirrhosis of the liver and ascites).
•	Renal failure (GFR <15 ml/min/1.73 m2).
•	Severe heart failure (NYHA III-IV), 
•	Treatment of post-operative pain after coronary bypass surgery (or use of a heart-lung machine).

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><em>General warning for the use of systemic non-steroidal anti-inflammatory drugs:</em></strong></p><p>Gastrointestinal ulceration, bleeding, or perforation may occur at any time during treatment with non-steroidal anti-inflammatory drugs (NSAIDs), whether COX-2 selective or not, even in the absence of warning symptoms or a predisposing history. To minimise this risk, the lowest effective dose should be given for the shortest possible duration of treatment.</p><p>Placebo-controlled studies have shown an increased risk of thrombotic cardiovascular and cerebrovascular complications with certain COX-2 selective inhibitors. It is not yet known whether this risk correlates directly with the COX-1&nbsp;/&nbsp;COX-2 selectivity of individual NSAIDs. As no comparable clinical study data are available at present for long-term treatment with the maximum dosage of diclofenac, the possibility of a similarly elevated risk cannot be ruled out. Until such data becomes available, a careful risk-benefit assessment must be carried out prior to using diclofenac in patients with clinically confirmed coronary heart disease, cerebrovascular disorders, peripheral arterial occlusive disease or considerable risk factors (e.g. hypertension, hyperlipidaemia, diabetes mellitus, smoking). Due to this risk, too, the lowest effective dose should be given for the shortest possible duration of treatment.</p><p>&nbsp;</p><p>The renal effects of NSAIDs include fluid retention with oedema and/or arterial hypertension. For this reason, diclofenac should be used with caution in patients with cardiac impairment and other conditions that predispose to fluid retention. Caution is also indicated in patients who take concomitant diuretics or ACE inhibitors, or who are at increased risk of hypovolaemia.</p><p>&nbsp;</p><p>The consequences are generally more serious in the elderly. If gastrointestinal bleeding or ulceration occurs in patients undergoing treatment with Voltaren, the medicinal product should be withdrawn.</p><p><strong>&nbsp;</strong></p><p><strong>Cutaneous reactions</strong></p><p>Serious skin reactions, some of them fatal, including exfoliative dermatitis, Stevens-Johnson syndrome and toxic epidermal necrolysis (Lyell&rsquo;s syndrome) and drug rash with eosinophilia and systemic symptoms (DRESS) have been reported very rarely in association with the use of NSAIDs, including Voltaren (see section 4.8 Undesirable effects). Patients appear to be at the highest risk at the start of treatment, with : the onset of the reaction occurring in within the first month of treatment. Voltaren should be discontinued at the first apperance sign of rash, mucosal lesions or any other signs of hypersensitivity.</p><p>&nbsp;</p><p>As with other NSAIDs, allergic reactions &ndash; including anaphylactic/anaphylactoid reactions &ndash; may occur in rare cases, even without prior exposure to diclofenac.</p><p><strong><em>&nbsp;</em></strong></p><p><strong>Masking signs of infection</strong></p><p>Its pharmacodynamic properties mean that, like other NSAIDs, diclofenac may mask the signs and symptoms of infection.</p><p>&nbsp;</p><p><strong><em>Precautions</em></strong></p><p><strong>&nbsp;</strong></p><p><strong>General</strong></p><p>&nbsp;</p><p>The concomitant use of Voltaren with systemic NSAIDs including cyclooxygenase-2 selective inhibitors should be avoided due to the potential for additive addverse effects (see section 4.5 Interactions with other medicaments and other forms of interaction).</p><p>&nbsp;</p><p>Caution is required in the elderly patients on basic medical grounds. In particular, it is recommended that the lowest effective dose be used in frail elderly patients or those with a low body weight</p><p>&nbsp;</p><p>Voltaren Retard/SR tablets contain sucrose and therefore are not recommended for patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency.</p><p>&nbsp;</p><p>This medicine contains less than 1 mmol (23 mg) of sodium per dosage unit (coated tablet, prolonged-release tablet and drops), making it practically &ldquo;sodium-free&rdquo;.</p><p><strong>&nbsp;</strong></p><p><strong>Respiratory effects (Pre-existing asthma): </strong></p><p>In patients with asthma, seasonal allergic rhinitis, swelling of the nasal mucosa (i.e. nasal polyps), chronic obstructive pulmonary diseases or chronic infections of the respiratory tract (especially if linked to allergic rhinitis-like symptoms), reactions on NSAIDs like asthma exacerbations (intolerance to analgesics / analgesics-induced asthma), Quincke&rsquo;s oedema or urticaria are more frequent than in other patients. Therefore, special precaution is recommended in such patients (readiness for emergency). This is applicable as well to patients with allergic reaction to other substances, e.g. rash, pruritus or urticaria.</p><p><em>&nbsp;</em></p><p><strong>Gastrointestinal effects:</strong></p><p>&nbsp;</p><p>As with all NSAIDs, including diclofenac close medical surveillance is imperative and particular caution should be excised when prescribing diclofenac in patients with symptoms indicative of gastrointestinal disorders, or with a history suggestive of gastric or intestinal ulceration, bleeding or perforation (see section 4.8 Undesirable effects).&nbsp; The risk of GI bleeding, is higher with increasing NSAID doses and in patients with a history of ulcer, (particularly if complicated with bleeding or perforation) and in elderly patients. .</p><p>&nbsp;</p><p>Treatment should be initiated and maintained at the lowest effective dose in order to reduce the risk of GI toxicity in patients with a history of ulcers (particularly if complicated by bleeding or perforation) and in elderly patients.</p><p>&nbsp;</p><p>Combination therapy with protective agents (e.g. misoprostol or proton pump inhibitors) should be considered for these patients, and also for patients requiring concomitant use of low dose acetylsalicylic acid (ASA) / or other drugs likely to increase gastrointestinal risk.</p><p>&nbsp;</p><p>Patients with a history of GI toxicity, particularly elderly patient, should report any unusual abdominal symptoms (especially GI bleeding).</p><p>Caution is recommended in patients receiving concomitant medications which could increase the risk of ulceration or bleeding, such as systemic corticosteroids, anticoagulants, selective serotonin-reuptake inhibitors (SSRIs) or anti-platelet agents (see section 4.5 Interaction with other medicaments and other forms of interaction).</p><p>&nbsp;</p><p>NSAIDs, including diclofenac, can be associated with an increased risk of a gastrointestinal anastomosis leak. Caution is required with the use of Voltaren after gastrointestinal surgery and close medical monitoring is recommended.</p><p><strong>&nbsp;</strong></p><p><strong>Hepatic effects:</strong></p><p>Close medical surveillance is required when prescribing Voltaren to patients with impairment of hepatic function as their condition may be exacerbated. (see section 4.8 Undesirable effects).</p><p>&nbsp;</p><p>As with other NSAIDs, including diclofenac, levels of one or more liver enzymes may rise during treatment with Voltaren&nbsp;. This has been observed very frequently with diclofenac in clinical studies (in approximately 15% of patients), but is very rarely accompanied by clinical symptoms. Most of these cases involve borderline increases. Frequently (in 2.5% of cases) the increases observed were moderate (&ge; 3 to &lt;&nbsp;8&nbsp;times the upper limit of normal), while the incidence of marked increases (&ge; 8&nbsp;times the upper limit of normal) remained around 1%. Elevated liver enzyme levels were accompanied by clinically manifest liver damage in 0.5% of cases in the above-mentioned clinical studies. Elevated enzyme levels were generally reversible after discontinuation of the drug.</p><p>&nbsp;</p><p>As with other NSAIDs, long-term &nbsp;treatment with Diclofenac, calls for regular monitoring of liver enzyme levels.</p><p>&nbsp;</p><p>Voltaren should be discontinued. if abnormal liver function tests persist or worsen, if clinical signs or symptoms suggestive of liver disease develop or if other manifestations occur (e.g. eosinophilia, rash),</p><p>&nbsp;</p><p>In addition to elevated liver enzymes, there have been rare reports of severe hepatic reactions, including jaundice and fulminant hepatitis, hepatic necrosis and hepatic failure which, in isolated cases, had a fatal outcome.</p><p>&nbsp;</p><p>Hepatitis may develop &nbsp;without prodromal symptoms.&nbsp;</p><p>Caution is required for when using diclofenac in patients with hepatic porphyria, since it may trigger an attack.</p><p>&nbsp;</p><p><strong>Renal effects: &nbsp;</strong></p><p>Owing to the importance of prostaglandins in maintaining renal blood flow, prolonged treatment with high doses of NSAIDs, including diclofenac, frequently (1&ndash;10%) results in oedema and hypertension. Particular caution is required in patients with impaired cardiac or renal function, history of hypertension, the elderly, patients receiving concomitant treatment with diuretics or medicinal products that can significantly impact renal function, and those patients with substantial extracellular volume depletion from any cause, e.g. before or after major surgery (see section 4.3 Contraindications).</p><p>&nbsp;</p><p>Monitoring of renal function is recommended as a precautionary measure when using diclofenac in such cases. Discontinuation of therapy is usually followed by recovery to the pre-treatment state.</p><p><strong>&nbsp;</strong></p><p><strong>Cardiovascular and cerebrovascular effects: </strong></p><p>Treatment with NSAIDs including diclofenac, particularly at high doses and for prolonged periods, may be associated with a slightly increased risk of serious cardiovascular thrombotic events (including myocardial infarction and stroke).</p><p>&nbsp;</p><p>Treatment with Voltaren is generally not recommended in patients with established cardiovascular disease (heart failure, established ischaemic heart disease, peripheral arterial disease) or uncontrolled hypertension. If needed, patients with established cardiovascular disease, uncontrolled hypertension or significant risk factors for cardiovascular disease (e.g. hypertension, hyperlipidaemia, diabetes mellitus and smoking) should be treated with Voltaren only after careful consideration and only at doses of up to 100 mg daily if treated for more than 4 weeks.</p><p>&nbsp;</p><p>As the cardiovascular risks of diclofenac may increase with dose and duration of exposure, the lowest effective daily dose should be used for the shortest duration possible. The patient&#39;s need for symptomatic relief and response to therapy should be re-evaluated periodically, especially when treatment continues for more than 4 weeks.</p><p>Patients should remain alert for the signs and symptoms of serious arterial thromboembolic events (e.g. chest pain, shortness of breath, weakness, slurring of speech), which can occur without warning. Patients should be instructed to see a physician immediately in case of such an event.</p><p>&nbsp;</p><p><strong>Haematological effects:</strong></p><p>As with other NSAIDs, complete blood counts are recommended during long-term treatment with Voltaren Retard/SR.</p><p>&nbsp;</p><p>Voltaren may temporarily inhibit platelet aggregation Patients with coagulation disorders should be carefully monitored.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The following interactions include those observed with Voltaren Retard/SR tablets and/or other pharmaceutical forms of diclofenac.</p><p>&nbsp;</p><p><strong><u>Observed interactions to be considered</u></strong></p><p>&nbsp;</p><p><strong>CYP2C9 inhibitors:</strong> Caution is recommended when co-prescribing diclofenac with CYP2C9 inhibitors (such as voriconazole), which could result in a significant increase in peak plasma concentrations and exposure to diclofenac</p><p>&nbsp;</p><p><strong>CYP2C9 inducers:</strong><strong> </strong>Caution is required when co-administering diclofenac with CYP2C9 inducers (such as rifampicin). This could result in a significant decrease in plasma concentration and exposure to diclofenac.</p><p><strong>&nbsp;</strong></p><p><strong>Lithium:<em> </em></strong>Diclofenac may increase plasma concentrations of co-administered lithium. Monitoring of the serum lithium level is recommended.</p><p>&nbsp;</p><p><strong>Digoxin:</strong>&nbsp; Diclofenac may raise plasma concentrations of co-administered digoxin. Monitoring of the serum digoxin level is recommended.</p><p>&nbsp;</p><p><strong>Diuretics and antihypertensive agents:</strong>&nbsp; As other NSAIDs, co-administeration of Voltaren may reduce the antihypertensive effects of diuretics and antihypertensive agents (e.g. beta-blockers, angiotensin converting enzyme (ACE) inhibitors</p><p>&nbsp;</p><p>Therefore, the combination should be administered with caution and patients, especially the elderly, should have their blood pressure periodically monitored. Patients should be adequately hydrated and consideration should be given to monitoring of renal function after initiation of concomitant therapy periodically thereafter, particularly for diuretics and ACE inhibitors due to the increased risk of nephrotoxicity. (see section 4.4 Special warnings and precautions for use).</p><p>&nbsp;</p><p><strong>Ciclosporin and Tacrolimus:</strong>&nbsp; Diclofenac, like other NSAIDs, may increase the nephrotoxicity of ciclosporin and tacrolimus due to the effect on renal prostaglandins. Therefore, it should be given at doses lower than those that would be used in patients not receiving ciclosporin or Tacrolimus.&nbsp;</p><p>&nbsp;</p><p><strong>&nbsp;Drugs known to cause hyperkalemia</strong>: Concomitant treatment with potassium-sparing diuretics, ciclosporin, tacrolimus or trimethoprim may be associated with increased serum potassium levels, which should therefore be monitored frequently (see section 4.4 Special warnings and precautions for use).</p><p>&nbsp;</p><p><strong>Quinolone antibiotics: </strong>There have been isolated reports of convulsions that may have been due to concomitant use of quinolones and NSAIDs.</p><p><strong>&nbsp;</strong></p><p><strong><u>Anticipated interactions to be considered</u></strong></p><p><strong><u>&nbsp;</u></strong></p><p><strong>Other NSAIDs and corticosteroids:</strong>&nbsp; Co-administration of diclofenac with other systemic NSAIDs or corticosteroids may increase the frequency of gastrointestinal adverse effects (see section 4.4 Special warnings and precautions for use).</p><p>&nbsp;</p><p><strong>Anticoagulants and anti-platelet agents:</strong>&nbsp; Caution is recommended since concomitant administration could increase the risk of bleeding (see section 4.4 Special warnings and precautions for use).&nbsp; Although clinical investigations do not appear to indicate that diclofenac affects the action of anticoagulants, there have been reports of an increased risk of bleeding in patients receiving diclofenac and anticoagulant concomitantly, close monitoring of such patients is recommended.</p><p>&nbsp;</p><p><strong>Selective serotonin reuptake inhibitors (SSRIs):</strong> Concomitant administration of SSRI&rsquo;s may increase the risk of gastrointestinal bleeding (see section 4.4 Special warnings and precautions for use).</p><p>&nbsp;</p><p><strong>Antidiabetics:</strong>&nbsp; Clinical studies have shown that Voltaren can be given together with oral antidiabetic agents without influencing their clinical effect.&nbsp; However there have been isolated reports of hypoglycaemic and hyperglycaemic reactions following administration of diclofenac requiring adjustment of the dosage of the antidiabetic agents. For this reason, monitoring of the blood glucose level is recommended as a precautionary measure during concomitant therapy.</p><p>There have also been isolated reports of metabolic acidosis when diclofenac was co-administered with, especially in patients with pre-existing renal impairment.</p><p>&nbsp;</p><p><strong>Methotrexate:</strong> Caution is recommended when NSAIDs, including diclofenac, are administered less than 24 hours before or after treatment with methotrexate, since blood levels of methotrexate may rise and the toxicity of this substance be increase.</p><p><strong>&nbsp;</strong></p><p><strong>Phenytoin:</strong> When using phenytoin concomitantly with diclofenac, monitoring of phenytoin plasma concentrations is recommended due to an expected increase in exposure to phenytoin.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Pregnancy</strong></p><p>Inhibition of prostaglandin synthesis may have negative impact on pregnancy and/or the embryo/foetal development. Data from epidemiological studies suggest an increased risk of miscarriage and or cardiac malformation and gastroschisis after use of a prostaglandin synthetase inhibitor in early pregnancy. The risk is believed to increase with dose and duration of therapy.</p><p>&nbsp;</p><p>In animals, administration of a prostaglandin synthetase inhibitor has shown to result in increased pre-and post-implantation loss and embryo-foetal lethality.</p><p>&nbsp;</p><p>In addition, increased incidences of various malformations, including cardiovascular malformation, have been reported in animals given a prostaglandin synthetase inhibitor during organogenesis (see section 5.3 preclinical safety data)</p><p>&nbsp;</p><p><u>First/second trimester</u></p><p>During the first and second trimesters of pregnancy, diclofenac should not be given unless absolutely necessary. If Voltaren is used by a woman attempting to conceive, or during the 1st or 2nd trimester of pregnancy, the dose should be kept as low and duration of treatment as short as possible.</p><p>&nbsp;</p><p><u>Oligohydramnios/neonatal renal impairment</u></p><p>Use of NSAIDs in the 20th week of pregnancy or later may lead to fetal renal impairment, which may cause oligohydramnios and, in some cases, neonatal renal impairment. These adverse effects occur, on average, after days to weeks of treatment, although in rare cases oligohydramnios has been reported as early as 48 hours after initiation of NSAID treatment. Oligohydramnios is often, but not always, reversible with treatment discontinuation. Complications of prolonged oligohydramnios may, for example, include limb contractures and delayed lung maturation. In some post-marketing cases of neonatal renal impairment invasive procedures such as exchange transfusion or dialysis were required. Consider ultrasound monitoring of the amniotic fluid if Voltaren treatment lasts longer than 48 hours. Discontinue Voltaren if oligohydramnios occurs and follow up according to clinical practice.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Third trimester</u></p><p>Diclofenac is contraindicated during the third trimester of pregnancy. All prostaglandin synthetase inhibitors may:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; expose the foetus to:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; cardiopulmonary toxicity (with premature closure of the ductus arteriosus and pulmonary hypertension) (see section 5.3 preclinical safety data)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; renal dysfunction, which may progress to renal failure with oligohydroamniosis</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; expose the mother and child to the following risks:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; possible prolongation of bleeding time, an effect of inhibition of platelet aggregation even at very low doses</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inhibition of uterine contractions resulting in delayed or prolonged labour</p><p>&nbsp;</p><p>Consequently, Voltaren is contraindicated during the third trimester of pregnancy.</p><p>&nbsp;</p><p><strong>Lactation</strong></p><p>As with other NSAIDs, diclofenac passes into breast milk in small amounts. As a precaution, Therefore Voltaren Retard/SR tablets should not be administered during breast feeding in order to avoid undesirable effects in the infant. If treatment is essential, the infant should be switched to bottle feeding.</p><p>&nbsp;</p><p><strong>fertility</strong></p><p>the use of diclofenac may impair female fertility and is not recommended in women attempting to conceive. Consideration should be given to stopping diclofenac in women who may have difficulties conceiving, or in those being tested for infertility.</p><p>&nbsp;</p><p>In animals, based on relevant data, impairment of male fertility cannot be ruled out (see &quot;Section 5.3 Preclinical safety data&quot;). The relevance of this finding for humans is unclear.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Patients who experience visual disturbances, light-headedness, dizziness, , drowsiness, or other central nervous system disturbances while taking Voltaren retard or SR &nbsp;should refrain from driving or using machinery.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Adverse reactions are ranked under the heading of frequency, the most frequent first, using the following convention: very common: (<em>&ge;</em>1/10); common (&ge; 1/100, &lt;1/10); uncommon (&ge; 1/1,000, &lt;1/100); rare (&ge;1/10,000 &lt;1/1000); very rare (&lt;1/10,000); not known: cannot be estimated from available data.</p><p>&nbsp;</p><p>The following undesirable effects include those reported with other short-term or long-term use.</p><p><em>&nbsp;</em></p><p><strong>Table 1</strong></p><p><em>&nbsp;</em></p><table border="1" cellspacing="0" cellpadding="0" style="width:612px"><tbody><tr><td colspan="2" style="vertical-align:top"><p><strong>Blood and lymphatic system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Thrombocytopenia, leucopoenia, anaemia (including haemolytic and aplastic anaemia), agranulocytosis.</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Immune system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Rare</p><p>&nbsp;</p><p>Very rare</p></td><td style="vertical-align:top"><p>Hypersensitivity, anaphylactic and anaphylactoid reactions (including hypotension and shock).</p><p>Angiooedema (including face oedema).</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Psychiatric disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Very rare</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p>Disorientation, depression, insomnia, nightmare, irritability, psychotic disorder.</p><p>&nbsp;</p><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Nervous system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p><p>Rare</p><p>Very rare</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p>Headache, light-headedness.</p><p>Somnolence,</p><p>Paraesthesia, memory impairment, convulsion, anxiety, tremor, aseptic meningitis, dysgeusia, cerebrovascular accident.</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Eye disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Very rare</p><p>Unknown</p></td><td style="vertical-align:top"><p>Visual disturbance, visual impairment , diplopia.</p><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Ear and labyrinth disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p><p>Very rare</p></td><td style="vertical-align:top"><p>Vertigo.</p><p>Tinnitus, hearing impaired.</p><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Cardiac disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon*</p><p>&nbsp;</p><p>&nbsp;</p><p>Frequency not known:</p></td><td style="vertical-align:top"><p>Myocardial infarction, cardiac failure, palpitations, chest pain.</p><p>&nbsp;</p><p>Kounis syndrome</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Vascular disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p><p>Very rare</p></td><td style="vertical-align:top"><p>Hypertension</p><p>vasculitis.</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Respiratory, thoracic and mediastinal disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Rare</p><p>Very rare</p></td><td style="vertical-align:top"><p>Asthma (including dyspnoea).</p><p>Pneumonitis.</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Gastrointestinal disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p><p>&nbsp;</p><p>Rare</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Very rare</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p>Nausea, vomiting, diarrhoea, dyspepsia, abdominal pain, flatulence, decreased appetite.</p><p>Gastritis, gastrointestinal haemorrhage, haematemesis, haemorrhagic diarrhoea, melaena, gastrointestinal ulcer (with or without bleeding, gastrointestinal stenosis&nbsp; or perforation, which may lead to peritonitis)</p><p>Colitis (including haemorrhagic colitis, ischaemic colitis and exacerbation of ulcerative colitis or Crohn&#39;s disease), constipation, stomatitis,glossitis, oesophageal disorder, intestinal diaphragm diease, pancreatitis.</p><p>&nbsp;</p><p>Voltaren Retard/SR may provoke chronic inflammatory conditions with pseudomembranes and strictures in the lower intestines (small and large intestines)</p><p>&nbsp;</p><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Hepatobiliary disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p><p>Rare</p><p>Very rare</p></td><td style="vertical-align:top"><p>Transaminases increased.</p><p>Hepatitis, jaundice, hepatic dysfunction</p><p>Fulminant hepatitis, hepatic necrosis, hepatic failure.</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Skin and subcutaneous tissue disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p><p>Rare</p><p>Very rare</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Not known:</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p>Rash.</p><p>Urticaria.</p><p>Bullous dermatitis, eczema, erythema, erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis (Lyell&#39;s syndrome), dermatitis exfoliative, alopecia, photosensitivity reaction, purpura, Henoch-Schoenlein &nbsp;purpura, pruritus.</p><p>&nbsp;</p><p>Drug rash with eosinophilia and systemic symptoms (DRESS)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Renal and urinary disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p><p>&nbsp;</p><p>Very rare</p></td><td style="vertical-align:top"><p>Fluid retention, oedema.</p><p>&nbsp;</p><p>Acute renal failure, haematuria, proteinuria, nephrotic syndrome, tubulointerstitial nephritis, renal papillary necrosis.</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>General disorders and administration site conditions</strong></p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Oedema</p></td></tr></tbody></table><p><em>* The frequency reflects data from long-term treatment with a high dose (150 mg/day).</em></p><p><em>&nbsp;</em></p><p>Meta-analyses of controlled Clinical trial and pharmaepidemiological data point towards an increased risk of arterial thromboembolic events (for example myocardial infarction or stroke) associated with the use of diclofenac, particularly at high doses (150mg daily) and in long term treatment (see section 4.4 &ldquo;Special warnings and precautions for use&rdquo;).</p><p><em>&nbsp;</em></p><p><em>Visual effects</em></p><p>Visual disturbances such as visual impairment, blurred vision and diplopia appear to be NSAID class effects and are usually reversible on discontinuation. A likely mechanism for the visual disturbances is the inhibition of prostaglandin synthesis and other related compounds that alter the regulation of retinal blood flow resulting in potential changes in vision. If such symptoms occur during diclofenac treatment, an ophthalmological examination may be considered to exclude other causes.</p><p><em>&nbsp;</em></p><p><u>Reporting of suspected adverse reactions</u></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions</p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>To report any side effect(s):</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Saudi Arabia</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Saudi Food and Drug Authority National Pharmacovigilance Center (NPC):</strong></p><p>&nbsp;</p><p>o Fax: +966112057662</p><p>o Call NPC at +966-11-2038222, Exts: 2317-2356-2340.</p><p>o Toll free phone: 8002490000</p><p>o SFDA call center: 19999</p><p>o E-mail: npc.drug@sfda.gov.sa</p><p>o Website: https://ade.sfda.gov.sa</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Patient Safety Department Novartis Consulting AG - Saudi Arabia:</strong></p><p>&nbsp;</p><p>o Toll Free Number: 8001240078</p><p>o Phone: +996112658100</p><p>o Fax: +966112658107</p><p>o Email: adverse.events@novartis.com</p><p>&nbsp;</p><p><strong>&bull;&nbsp;&nbsp;&nbsp; Other GCC States:</strong></p><p>-&nbsp; Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Symptoms</strong></p><p>There is no typical clinical picture resulting from diclofenac over dosage. Over dosage may cause symptoms such as vomiting, gastrointestinal bleeding, diarrhoea, light-headedness, tinnitus, convulsions.&nbsp; Acute renal failure and liver damage are possible in the event of severe intoxication.</p><p>&nbsp;</p><p><strong>Therapeutic measures</strong></p><p>Treatment of acute intoxication &nbsp;with NSAIDs, including diclofenac, essentially consists of supportive measures and symptomatic treatment. Supportive measures and symptomatic treatment should be given for complications such as hypotension, renal failure, convulsions, gastrointestinal disorder, and respiratory depression.</p><p>&nbsp;</p><p>Specific measures such as forced diuresis, dialysis or haemo-perfusion are unlikely to be helpful in eliminating NSAIDs, including diclofenac, due to their high protein binding and extensive metabolism.</p><p>&nbsp;</p><p>Activated charcoal may be considered after ingestion of a potentially toxic overdose, and gastric decontamination (e.g. vomiting, gastric lavage) after ingestion of a potentially life threatening overdose.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Pharmacotherapeutic group</strong></p><p>Nonsteroidal anti-inflammatory drugs (NSAIDs).</p><p>&nbsp;</p><p><strong>Mechanism of action</strong></p><p>Voltaren contains the sodium salt of diclofenac, a nonsteroidal agent with pronounced antirheumatic analgesic, anti- inflammatory &nbsp;and antipyretic activity.&nbsp;</p><p>&nbsp;</p><p>Inhibition of prostaglandin biosynthesis has been demonstrated experimentally and is considered fundamental to the mechanism of action of diclofenac. Prostaglandins play a major role in causing inflammation, pain and fever.</p><p><em>in vitro</em> at concentrations equivalent to the concentrations reached in human beings. Voltaren does not suppress proteoglycan biosynthesis in cartilage</p><p>&nbsp;</p><p><em>Clinical efficacy </em></p><p>In rheumatic diseases, the anti-inflammatory and analgesic properties of diclofenac elicit a clinical response characterised by improved function and marked relief of signs and symptoms such as pain at rest, pain on movement, morning stiffness and swelling of the joints. In post-traumatic and post-operative inflammatory conditions, Voltaren rapidly relieves both spontaneous pain and pain on movement, and reduces inflammatory swelling and wound oedema.</p><p>&nbsp;</p><p>In clinical trials, the product has also been shown to exert a pronounced analgesic effect in moderate and severe pain of non-rheumatic origin. It can relieve the pain, and also reduce bleeding, in primary dysmenorrhoea.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Absorption</strong></p><p>Judged on the basis of the urinary recovery of unchanged diclofenac and its hydroxylated metabolites, the same amount of diclofenac is released and absorbed from Voltaren Retard/SR as from the gastro-resistant tablets. However, on average the systemic bioavailability of diclofenac from Voltaren Retard/SR is approximately 82% of that attained with the same dose of Voltaren administered in the form of gastro-resistant tablets (possibly due to release-rate-dependent first-pass metabolism). Owing to the slower release of the active substance from Voltaren Retard/SR, peak plasma concentrations are lower than with the gastro-resistant tablets.</p><p>&nbsp;</p><p>Mean peak plasma concentrations of 0.5 &micro;g/ml and 0.4 &micro;g/ml are attained on average 4&nbsp;hours after administration, respectively, of 100&nbsp;mg or 75&nbsp;mg prolonged release tablets. Ingestion with food has no notable effect on the absorption and systemic bioavailability of Voltaren Retard/SR.</p><p>&nbsp;</p><p>On the other hand, mean plasma concentrations of 13&nbsp;ng/ml are recorded 24&nbsp;hours (16&nbsp;hours) after ingestion of 100&nbsp;mg (75&nbsp;mg).</p><p>&nbsp;</p><p>Ingestion of 100&nbsp;mg once daily or 75&nbsp;mg twice daily produces trough plasma levels of approximately 22&nbsp;ng/ml and 25&nbsp;ng/ml, respectively.</p><p>&nbsp;</p><p>Pharmacokinetic behaviour does not change on repeated administration.&nbsp; Accumulation does not occur, provided the recommended dosage intervals are observed. Plasma concentrations attained in children after equivalent doses (mg/kg body weight) are similar to those attained in adults.</p><p>&nbsp;</p><p><strong>Distribution</strong></p><p>The active substance is 99.7% protein bound, mainly to albumin (99.4%).</p><p>&nbsp;</p><p>The apparent volume of distribution has been calculated at 0.12 to 0.17 L/kg.</p><p>&nbsp;</p><p>Diclofenac enters the synovial fluid, where maximum concentrations are measured 2-4 hours after the peak plasma values have been attained. The apparent half-life for elimination from the synovial fluid is 3-6 hours. Two hours after reaching the peak plasma values, concentrations of the active substance are already higher in the synovial fluid than they are in the plasma and remain higher for up to 12 hours.</p><p>&nbsp;</p><p>Diclofenac was detected in a low concentration (100 ng/mL) in breast milk in one nursing mother. The estimated amount ingested by an infant consuming breast milk is equivalent to a 0.03 mg/kg/day dose</p><p><strong>&nbsp;</strong></p><p><strong>Metabolism</strong></p><p>Biotransformation of diclofenac is partly by glucuronidation of the intact molecule, but mainly by single and multiple hydroxylation and methoxylation. This results in several phenolic metabolites (3&#39;-hydroxy-, 4&#39;-hydroxy-, 5-hydroxy-, 4&#39;,5-dihydroxy- and 3&#39;-hydroxy-4&#39;-methoxy-diclofenac), most of which are subsequently converted to glucuronide conjugates. Two of these phenolic metabolites are pharmacologically active, but to a much lesser extent than diclofenac itself.</p><p><strong>&nbsp;</strong></p><p><strong>Elimination</strong></p><p>The total systemic clearance of diclofenac in plasma is 263 &plusmn; 56 mL/min (mean value &plusmn; SD). The terminal half-life in plasma is 1-2 hours. Four of the metabolites, including the two active ones, also have short plasma half-lives of 1-3 hours. The virtually inactive metabolite, 3&#39;-hydroxy-4&#39;-methoxy-diclofenac, has a much longer half-life.</p><p>&nbsp;</p><p>About 60% of the administered dose is excreted in the urine in the form of metabolites. compared with less than 1% as unchanged substance. The rest of the dose is eliminated as metabolites through the bile in the faeces.</p><p>&nbsp;</p><p><strong>Linearity/non-linearity</strong></p><p>The amount absorbed is in linear proportion to the size of the dose.</p><p><strong>&nbsp;</strong></p><p><strong>Characteristics in patients</strong></p><p><em>Elderly</em>:&nbsp; No relevant age-dependent differences in the drug&#39;s absorption, metabolism, or excretion have been observed,</p><p>&nbsp;</p><p><em>Patients with renal impairment:&nbsp; </em>In patients with renal impairment, no accumulation of the unchanged active substance with usual dosage schedule. In patients with &nbsp;a creatinine clearance of &lt;10 mL/min, the theoritical steady-state plasma levels of the metabolites are about 4 times higher than in normal subjects. However, the metabolites are ultimately cleared through the bile.</p><p>&nbsp;</p><p><em>Patients with hepatic disease:&nbsp; </em>In patients with chronic hepatitis or compensated cirrhosis, the pharmacokinetics and metabolism of diclofenac are the same as in patients without liver disease.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Preclinical data from safety pharmacology studies, acute and repeated dose toxicity studies and genotoxicity, mutagenicity and carcinogenicity studies with diclofenac revealed no evidence of a specific hazard for humans at the intended therapeutic doses.</p><p>&nbsp;</p><p>The increased incidence of lymphomas (thymus) in mice, and subcutaneous fibromas, fibroadenomas (mammary gland) or C-cell adenomas (thyroid gland) in rats were all within the historical control range of the laboratory for the animal strain used, and are considered to have occurred by chance.</p><p>&nbsp;</p><p>In all toxicity studies&nbsp;carried out in rats, hypertrophy of mesenteric lymph nodes or lymphadenitis with reactive hyperplasia were observed. These changes were accompanied by neutrophilia that was also observed in studies in monkeys. These are presumably secondary reactions to the ulcers observed in the gastrointestinal tract. In a two-year study, a dose-dependent increase in thrombotic vascular occlusions in the heart was observed in rats treated with diclofenac.</p><p>&nbsp;</p><p>Additional studies indicate that, with repeated oral doses in rats (&gt; 1 mg/kg body weight), diclofenac causes effects that influence fertility (lower testosterone level, and decreased epididymal and testicular weight in association with histopathological changes). Similar effects were also observed in the F1 generation following doses of &ge; 1.25 mg/kg in a two-generation study. In dogs, daily subcutaneous doses of 2 mg/kg diclofenac sodium led to an increased spermatid count. Further studies describe a decreased mating frequency in female rats following a repeated dose of &ge; 0.5 mg/kg diclofenac. For this reason, an influence on both male and female fertility cannot be ruled out.</p><p>&nbsp;</p><p>Diclofenac crosses the placental barrier in rodents. Administration of NSAIDs (including diclofenac) inhibited ovulation in rabbits and implantation and placentation in rats, and led to premature closure of the ductus arteriosus in pregnant rats. Maternally toxic doses of diclofenac were associated with dystocia, prolonged gestation, decreased fetal survival, and intrauterine growth retardation in rats. The slight effects of diclofenac on reproduction parameters and delivery as well as closure of the ductus arteriosus <em>in utero</em> are pharmacological effects of this class of prostaglandin synthetase inhibitors (see section &quot;4.3 Contraindications&quot; and &quot;4.6 Pregnancy/Breast-feeding&quot;).</p><p>&nbsp;</p><p>In a study in mice, teratogenicity (cleft palate) was observed at the maternally toxic dose of 4 mg/kg. In rats and rabbits, doses up to the maternally toxic level did not lead to teratogenic effects. Delayed ossification and reduced fetal weight in a study in rabbits were the only changes observed in these investigations.</p><p>&nbsp;</p><p>At maternally toxic doses, the perinatal and post-natal development of the offspring were impaired (fertility, see above, also birth weight and delayed post-natal growth).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The tablets also contain the following inactive ingredients:</p><p>&nbsp;</p><p><u>Tablet core</u></p><p>Sucrose (90.8 mg sucrose/75 mg coated tablet and 119 mg sucrose/100 mg coated tablet)</p><p>Cetyl alcohol</p><p>Polyvinylpyrrolidone</p><p>Silica</p><p>Magnesium stearate</p><p>&nbsp;</p><p><u>Tablet coat</u></p><p>Hydroxypropyl methylcellulose</p><p>Polysorbate 80</p><p>Talc</p><p>Titanium Dioxide (E171)</p><p>Iron Oxide (E172)</p><p>&nbsp;</p><p><u>Tablet polish</u></p><p>Polyethylene glycol</p><p>Sucrose</p><p>&nbsp;</p><p><u>Tablet printing ink</u></p><p>Shellac</p><p>Propylene glycol</p><p>Aluminium hydroxide</p><p>Iron oxide (E172)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>None known.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Three years.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30℃.</p><p>Protect from moisture</p><p>Store in the original package&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p>Medicines should be kept out of the reach of children.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>100 mg Retard tablet:</u></strong></p><p>The tablets are packed in PVC/PE/PVDC blister packs of 10 and 30.</p><p><strong><u>75 mg SR tablet:</u></strong></p><p>The tablets are packed in PVC/PE/PVDC blister packs of 20.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The tablets should be swallowed whole with liquid, preferably with meals.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                The Marketing Authorization Holder for this Product is Novartis Pharma AG. 
www.Novartis.com 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Sep 2022 by Swissmedic
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>